TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05415319

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Laboratory tasks in middle childhood/pre-adolescence
Description: Children will watch a 2-minute clip from a live-action movie and complete Storytelling and Mask tasks from the Laboratory Temperament Assessment Battery.
Study: NCT06340542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic Mobility exercises
Description: Exercises which focus on improve the mobility of the spine especially thoracic region was administered to the patients in different position including quadruped and standing position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Release technique
Description: Interventions include release the muscle tension, trigger point release and reducing stiffness of spine was administered
Study: NCT05048901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Oral Cabozantinib 40-60 mg daily .every 4 weeks as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Lanreotide 120 mg deep SC on day 1 every 4 weeks.every 4 weeks as a cycle
Study: NCT05236205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caries removal with a lowspeed drill
Description: 1. Initial periapical and interproximal radiographs;~2. Prophylaxis with toothbrush and fluoride toothpaste;~3. Relative isolation with lip bumper, cotton roll, and aspirator;~4. Microbiological sampling with ear curette for standardization of volume of carious tissue;~5. Removal of carious dentin with carbide burs and manual instruments;~6. Additional microbiological sampling;~7. Clinical inspection of texture of remaining dentin with an exploratory probe;~8. Restoration with glass ionomer cement (Ketac Molar Easy Mix - 3M ESPE);~9. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial removal of carious tissue with the administration of Papacarie™
Description: 1. Initial radiographs;~2. Relative isolation;~3. Microbiological sample with otoscope curette to standardize volume of carious tissue;~4. Application of Papacarie™ for 5 m inutes, removal of carious tissue around lateral walls of the cavity with noncutting curette and no removal of carious tissue on pulp floor;~5. Second microbiological sample of remaining dentin with curette;~6. Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~7. Restoration with glass ionomer cement;~8. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial removal of carious tissue with the administration of Papacarie™ and application of Bixa Orellana extract (20%)
Description: 1. Initial radiographs;~2. Relative isolation;~3. Microbiological sample with otoscope curette to standardize volume of carious tissue;~4. Application of Papacarie™ with Bixa Orellana extract (20%) for 5 minutes, removal of carious tissue around lateral walls of the cavity with noncutting curette;~5. Irradiation of dental tissue for 1 minute on a single point;~6. Second microbiological sample of remaining dentin with curette;~7. Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~8. Restoration with glass ionomer cement;~9. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment.
Study: NCT06188481

Intervention type: OTHER
Group type: OTHER
Intervention: whole-body electromyostimulation training
Description: The duration of the intervention is 16 weeks, the training frequency is 1.5 times a week and the exercise program consists of 20 minutes.
Study: NCT05236205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial removal of carious tissue with the administration of Papacarie™, application of Bixa Orellana extract (20%) and LED (aPDT)
Description: 1. Initial radiographs;~2. Relative isolation;~3. Microbiological sample with otoscope curette to standardize volume of carious tissue;~4. Application of Papacarie™ with Bixa Orellana extract (20%) for 5 minutes and the blue light-emitting diode (LED) irradiation with 440-480 nm. Removal of carious tissue around lateral walls of the cavity with noncutting curette;~5. Irradiation of dental tissue for 1 minute on a single point;~6. Second microbiological sample of remaining dentin with curette;~7. Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~8. Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);~9. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment.
Study: NCT04553939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 3mg/m2 ivgtt, D1 every 14 days for 2-4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 800mg/m2 ivgtt, D1 every 14 days for 2-4 cycles.
Study: NCT06188481

Intervention type: OTHER
Group type: OTHER
Intervention: activity tracker
Description: Participants wear the activity tracker on their wrist for the entire 16-week study period.

Intervention type: OTHER
Group type: OTHER
Intervention: activity tracker
Description: Participants wear the activity tracker on their wrist for the entire 16-week study period.
Study: NCT04771286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550 (C-14)
Description: BI 1015550 (C-14)
Study: NCT05495282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microvideo
Description: Asynchronous 10-minute micro-video on the topic for which no face-to-face interaction with faculty will be conducted.
Study: NCT05849727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH3821 tablets 200 mg
Description: TQH3821 is a Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQH3821 tablets 200 mg
Description: TQH3821 is a Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor.
Study: NCT06188481

Intervention type: OTHER
Group type: OTHER
Intervention: evidence-based lifestyle education program
Description: Participants receive an evidence-based lifestyle education programme (6 x 20 minutes for the period of 3 month).

Intervention type: OTHER
Group type: OTHER
Intervention: evidence-based lifestyle education program
Description: Participants receive an evidence-based lifestyle education programme (6 x 20 minutes for the period of 3 month).

Intervention type: OTHER
Group type: OTHER
Intervention: evidence-based lifestyle education program
Description: Participants receive an evidence-based lifestyle education programme (6 x 20 minutes for the period of 3 month).
Study: NCT04892966

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TXI Light Imaging
Description: Standard Colonoscopy using TXI imaging
Study: NCT04936282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grafalon
Description: When Borderline lesions are present in protocol biopsy, administer Grafalon ® 6 mg/kg/day in a single day. Then continue with the normal treatment: Steroids (5 mg/day), tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day).
Study: NCT04892966

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: WLI Imaging
Description: Standard Colonoscopy using White Light Imaging
Study: NCT04936282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Treatment
Description: When Borderline lesions are present in protocol biopsy, administer the normal treatment: Steroids (5 mg/day), tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day)
Study: NCT05139654

Intervention type: OTHER
Intervention: Arm elevation in the scapular plane
Description: Lift the arm up in the scapular plane

Intervention type: OTHER
Intervention: Arm elevation in the scapular plane
Description: Lift the arm up in the scapular plane

Intervention type: OTHER
Intervention: Pull up with gymbar
Description: Grasp the gymbar with both hands and pull up as high as the subject can

Intervention type: OTHER
Intervention: Pull up with gymbar
Description: Grasp the gymbar with both hands and pull up as high as the subject can

Intervention type: OTHER
Intervention: Pull up with fingerboard
Description: The width of the fingerboar is 20 mm. Pull up with fingers on the fingerboard.

Intervention type: OTHER
Intervention: Pull up with fingerboard
Description: The width of the fingerboar is 20 mm. Pull up with fingers on the fingerboard.
Study: NCT04852081

Intervention type: DRUG
Intervention: Palbociclib
Description: Palbociclib is in the form of oral capsules. Palbociclib, capsule, 125 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib should be taken with food
Study: NCT05824299

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: Patients will have TURBT under general anesthesia, which is induced with midazolam, propofol, sufentanil and rocuronium. The patients will be mechanically ventilated with laryngeal mask airway (LMA). Anesthesia will be maintained with sevoflurane/desflurane, propofol and remifentanil.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Description: Patients will have TURBT under spinal anesthesia. 10\~15mg of 0.5% ropivacaine will be injected in the subarachnoid cerebrospinal fluid at the levels of L2-L3 or L3-L4 in lumbar space. It will numb the nerve supply of the belly, hips, bottom as well as legs. The patient stays awake and won't feel any pain due to operation.
Study: NCT04961229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The Pfizer mRNA-based BNT162b2 vaccine
Description: participants who gave informed consent to participate in either the prospective non-randomised study or RCT will receive a single vaccine dose.~In addition, participants in the RCT will be randomised into two groups:~1. Third booster dose of BNT162b2 (one standard dose) with no change in immunosuppression protocol~2. Third booster dose of BNT162b2 (one standard dose) with immunosuppression reduction according to protocol (mycophenolic temporary cessation 4 days before (5 half-lives) and one week (expected antibody response) after vaccination (to allow for antibody response).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The Pfizer mRNA-based BNT162b2 vaccine
Description: participants who gave informed consent to participate in either the prospective non-randomised study or RCT will receive a single vaccine dose.~In addition, participants in the RCT will be randomised into two groups:~1. Third booster dose of BNT162b2 (one standard dose) with no change in immunosuppression protocol~2. Third booster dose of BNT162b2 (one standard dose) with immunosuppression reduction according to protocol (mycophenolic temporary cessation 4 days before (5 half-lives) and one week (expected antibody response) after vaccination (to allow for antibody response).
Study: NCT04852081

Intervention type: DRUG
Intervention: Ribociclib
Description: Ribociclib, tablets, 600mg orally (three 200 mg tablets)taken once daily with or without food for 21 consecutive days followed by 7 days off treatment

Intervention type: DRUG
Intervention: Abemaciclib
Description: Abemaciclib in combination with fulvestrant or an aromatase inhibitor: 150 mg twice daily Abemaciclib as monotherapy: 200 mg twice daily. (2.1)
Study: NCT04961229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The Pfizer mRNA-based BNT162b2 vaccine
Description: participants who gave informed consent to participate in either the prospective non-randomised study or RCT will receive a single vaccine dose.~In addition, participants in the RCT will be randomised into two groups:~1. Third booster dose of BNT162b2 (one standard dose) with no change in immunosuppression protocol~2. Third booster dose of BNT162b2 (one standard dose) with immunosuppression reduction according to protocol (mycophenolic temporary cessation 4 days before (5 half-lives) and one week (expected antibody response) after vaccination (to allow for antibody response).
Study: NCT05064202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella 5.5
Description: temporary Mechanical Circulatory Support (tMCS)

Intervention type: DRUG
Group type: OTHER
Intervention: Inotropes
Description: Enoximone, Dobutamine, Dopamine, Milrinone
Study: NCT05198115

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: aerobic training for 8 weeks, 3 times a week, and 60 min each time

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: aerobic exercise
Description: aerobic training for 8 weeks, 3 times a week, and 60 min each time
Study: NCT04976868

Intervention type: DRUG
Intervention: Pimecrolimus 1% Top Cream
Description: Elidel® as prescribed within routine clinical practice
Study: NCT05548218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated health education using a digital health pathway
Description: MyChart Care Companion is an interactive, individualized plan of care delivered to at-risk patients through user-friendly, accessible technology. Care Companion is a digital health pathway housed within EPIC. Care Companion features are integrated into the existing MyChart mobile app, which is part of Epic, and is available for iOS and Android devices. The interactive plan of care delivers notifications to patients' phones, prompts patients to complete educational session in the mobile app, analyzes questionnaire responses and patient-reported data, and orchestrates changes to the plan and escalations as needed to help patients, their caregivers, and care managers stay on top of the patient care. In addition to mobile phone, patients can also now access MyChart Care Companion on webpages via computers. The automated pathway assigns patient interactive health education materials during the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated health education using a digital health pathway
Description: MyChart Care Companion is an interactive, individualized plan of care delivered to at-risk patients through user-friendly, accessible technology. Care Companion is a digital health pathway housed within EPIC. Care Companion features are integrated into the existing MyChart mobile app, which is part of Epic, and is available for iOS and Android devices. The interactive plan of care delivers notifications to patients' phones, prompts patients to complete educational session in the mobile app, analyzes questionnaire responses and patient-reported data, and orchestrates changes to the plan and escalations as needed to help patients, their caregivers, and care managers stay on top of the patient care. In addition to mobile phone, patients can also now access MyChart Care Companion on webpages via computers. The automated pathway assigns patient interactive health education materials during the study.
Study: NCT04863456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total resection
Description: Total resection of HIPA in a single surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total resection
Description: Total resection of HIPA in a single surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Staged resection
Description: HIPA was resected subtotally at first time, and the tumor remnant was removed at a later date

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Staged resection
Description: HIPA was resected subtotally at first time, and the tumor remnant was removed at a later date

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subtotal resection followed by stereotactic radiation therapy
Description: HIPA was resected subtotally at first time, and the tumor remnant was controled by the stereotactic radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subtotal resection followed by stereotactic radiation therapy
Description: HIPA was resected subtotally at first time, and the tumor remnant was controled by the stereotactic radiation therapy
Study: NCT06526871

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser acceleration
Description: This intervention involves the application of Low-Level Laser Therapy (LLLT) using the Epic X device for patients undergoing orthodontic treatment. The protocol is designed to assess the effects of LLLT on pain reduction and treatment efficacy during the initial leveling and alignment phase of orthodontic therapy using clear aligners .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clear aligner therapy
Description: Clear aligner therapy involves using a series of custom-made, clear plastic aligners to gradually move teeth into their desired positions. These aligners are worn over the teeth and are typically changed every week as the teeth gradually shift. The treatment process starts with a digital scan or impression of the teeth, which is used to create a 3D model. This model helps in planning the precise movements needed to achieve proper alignment. Throughout the treatment, patients visit their orthodontist periodically to monitor progress and receive new sets of aligners. Clear aligners are popular for their aesthetic appeal and the convenience they offer compared to traditional braces.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: clear aligner therapy
Description: Clear aligner therapy involves using a series of custom-made, clear plastic aligners to gradually move teeth into their desired positions. These aligners are worn over the teeth and are typically changed every week as the teeth gradually shift. The treatment process starts with a digital scan or impression of the teeth, which is used to create a 3D model. This model helps in planning the precise movements needed to achieve proper alignment. Throughout the treatment, patients visit their orthodontist periodically to monitor progress and receive new sets of aligners. Clear aligners are popular for their aesthetic appeal and the convenience they offer compared to traditional braces.
Study: NCT06530290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 MG
Description: Mirtazapine (15 mg), once a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once a day, for 12 weeks
Study: NCT05895981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G132 system, Beijing PINS Medical Co., China
Description: Neuromodulation was performed according to the usual protocol
Study: NCT04829279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONNECT AI system group
Description: A. During the Intervention period, paramedics wear equipment for multi-faceted data acquisition and press the start button of the system.~B. During the Intervention period, inside the ambulance, a application that implements a function that automatically evaluates the patient's severity, displays a list of optimal transfer hospitals based on this, and shares real-time information of the hospitals, is installed so that paramedics can refer to the work.~C. ED's medical staff will receive through ER-kiosk pre-hospital patient information collected and analyzed through the CONNECT AI system before arrival.
Study: NCT04852081

Intervention type: DRUG
Intervention: Letrozole
Description: Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.

Intervention type: DRUG
Intervention: Anastrozole
Description: Anastrozole will be dosed daily at a fixed dose of 1 mg/day throughout the study.

Intervention type: DRUG
Intervention: Tamoxifen
Description: Tamoxifen will be dosed daily at a fixed dose of 20 mg/day throughout the study.

Intervention type: DRUG
Intervention: Fulvestrant
Description: Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.

Intervention type: DRUG
Intervention: Exemestane
Description: Exemestane will be dosed daily at a fixed dose of 25mg/day throughout the study.

Intervention type: DRUG
Intervention: Alpelisib
Description: Alpelisib will be dosed daily at a fixed dose of 300 mg/day throughout the study.
Study: NCT06204172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intensive Neurowave Emotional Stimulation (INES)
Description: Patients will undergo Neurowave-assisted multisensory stimulation five days a week for four weeks, featuring emotionally significant audio-visual content tied to personal history. Control group participants will experience primary auditory stimulation through familiar sounds, following a traditional rehabilitation approach mimicking the experimental group's frequency and intensity but without Neurowave use. This allows for a meaningful comparison of the two groups' experiences.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Sensorial Emotional Stimulation (ISES)
Description: The Intensive Sensorial Emotional Stimulation (ISES) in the control group involves primary auditory stimulation with emotionally rich everyday sounds, including familiar voices, favorite songs, and sounds related to daily life and past activities. It mimics the experimental group's frequency and intensity, lasting 45 minutes per session, five days a week, for four weeks. Unlike the experimental group using Neurowave, the control group follows a traditional rehabilitation approach with paper materials, live photos, face-to-face interaction, and classic music tapes, facilitating a meaningful comparison between the two groups' experiences.
Study: NCT05849727

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQH3821 tablets matching placebo
Description: TQH3821 tablets matching placebo without active substance.
Study: NCT05155826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: The patient will benefit from the placement of Cook's balloon (standard care) with the placement of the virtual reality headset on the examination table with the launch of the software before the beginning of the procedure. The virtual reality helmet will be removed at the end of the procedure.
Study: NCT06447220

Intervention type: DRUG
Intervention: washed microbiota transplantation
Description: The prepared microbiota suspension was infused into the patients' gut.
Study: NCT06407895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Limb Fitness Program
Description: the stability of the core area can help to improve dynamic balance, coordinate the upper and lower trunk muscles, and reduce muscles' damage and abnormalities. Physiotherapy had a role in programming training for Down Syndrome children, for example, using squat to stand training that seemed to improving lower extremity muscle power. Squat-to-stand training will stimulate the proprioceptive stimulation on the trunk and lower extremity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Therapy
Description: In control group routine therapy will be given 3 times a week for 6 weeks with session conducting 45 minutes per sessions which involve standing balance exercises, sitting from chair to stand, heal to toe stand will be performed.